Article Versions Notes

Sahin KB, Shah ET, Ferguson GP, Molloy C, Kalita-de Croft P, Hayes SA, Hudson A, Colvin E, Kamitakahara H, Harvie R, et al. Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers. 2021; 13(18):4651. https://doi.org/10.3390/cancers13184651

Sahin, Katherine B., Esha T. Shah, Genevieve P. Ferguson, Christopher Molloy, Priyakshi Kalita-de Croft, Sarah A. Hayes, Amanda Hudson, Emily Colvin, Hannah Kamitakahara, Rozelle Harvie, and et al. 2021. "Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer" Cancers 13, no. 18: 4651. https://doi.org/10.3390/cancers13184651

Sahin, K. B., Shah, E. T., Ferguson, G. P., Molloy, C., Kalita-de Croft, P., Hayes, S. A., Hudson, A., Colvin, E., Kamitakahara, H., Harvie, R., Hasovits, C., Khan, T., Duijf, P. H. G., Howell, V. M., He, Y., Bolderson, E., Hooper, J. D., Lakhani, S. R., Richard, D. J., ... Adams, M. N. (2021). Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 13(18), 4651. https://doi.org/10.3390/cancers13184651